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Abstract In this paper we describe isolation and molecular
characterization of human dihydroxyacetonephosphate acyl-
transferase (DAP-AT). The enzyme was extracted from rabbit
Harderian gland peroxisomes and isolated as a trimeric complex
by sucrose density gradient centrifugation. From peptide
sequences matching EST-clones were obtained which allowed
cloning and sequencing of the cDNA from a human cDNA
library. The nucleotide-derived amino acid sequence revealed a
protein consisting of 680 amino acid residues of molecular mass
77 187 containing a C-terminal type 1 peroxisomal targeting
signal. Monospecific antibodies raised against this polypeptide
efficiently immunoprecipitated DAP-AT activity from solubi-
lized peroxisomal preparations, thus demonstrating that the
cloned cDNA codes for DAP-AT.
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1. Introduction
Among the glycerophospholipids, ether phospholipids
(EPLs) including plasmalogens (PMs) represent a special sub-
class distinguished by their ether and vinylether bond on C-1
of the glycerol moiety, respectively. Although biochemists
have paid much attention to the ester-bonded glycerophos-
pholipids, EPLs and PMs are much less explored. Except
platelet activating factor (PAF) [1^4], which has been impli-
cated in processes involving immune complexes, endotoxins
and reperfusion, the physiological function of EPLs and
PMs are not well understood. Jones and Hajra [5] were the
¢rst to show that dihydroxyacetonephosphate acyltransferase
(DAP-AT), the key enzyme in EPL biosynthesis, is exclusively
localized within peroxisomes. To date, it is ¢rmly established
that the ¢rst three enzymes of EPL biosynthesis, DAP-AT,
alkyl-DAP synthase (ADAP-S) and most of acyl/alkyl-DAP-
reductase (ADAP-R) are localized to peroxisomes, while parts
of ADAP-R as well as the enzymes required to complete EPL
and PM biosynthesis are all found within the endoplasmic
reticulum (ER) [6^8]. ADAP-S which was recently cloned
and sequenced [9] is synthesized with a peroxisomal targeting
signal type 2 (PTS2) known to be su⁄cient to target a protein
to peroxisomes [10].
PMs are strongly de¢cient in patients su¡ering from gener-
alized peroxisomal disorders, such as the cerebro-hepato-renal
(Zellweger) syndrome [11,12], in which functional peroxisomes
are absent. This points not only to an important role of per-
oxisomes in EPL and PM biosynthesis but also to essential
functions of EPLs and PMs during ontogenesis. Within the
last years various functions were attributed to PMs. The sur-
face charge and the particular geometry of these lipids reduce
membrane £uidity [13] and in£uence the temperature of phase
transition [14] and structure of phospholipids [15]. A potential
role of PMs in protecting cells against oxidative stress has
been suggested by Zoeller et al. [16]. A similar function
PMs may exert in serum lipoproteins in which they occur in
low amounts [17,18]. Another interesting aspect of PMs is
their putative role in signal transduction. In several tissues
PMs have been demonstrated to predominantly contain at
their sn-2 position arachidonic acid which is released upon
proper stimulation [19,20]. Thus, PMs may function as mem-
brane-localized stores of arachidonic acid. Consistent with
this idea is the presence of a Ca2-independent PM-selective
phospholipase A2 which has been identi¢ed in cytosolic frac-
tions of the canine myocardium [21^23] as well as in neural
membranes [24] suggesting that the breakdown of PMs is a
receptor-mediated process delivering potential second messen-
gers, such as arachidonic acid and eicosanoids.
In the present paper we describe morphology and isolation
of peroxisomes of the Harderian gland of the rabbit, one of
the richest sources for DAP-AT [25^27], isolation of the active
enzyme from these peroxisomes as well as cloning and se-
quencing of its cDNA from a human brain cDNA library.
Biochemical as well as immunological studies suggest that
DAP-AT and ADAP-S form a stable complex within peroxi-
somes that catalyzes ether bond formation. The molecular
characterization of DAP-AT may o¡er great possibilities for
future studies dealing with the physiological function of EPLs
and PMs.
2. Material and methods
Harderian glands of male and female rabbits were obtained from a
local breeder. The red portion of 100^120 glands (60 g wet weight of
tissue) were homogenized in 0.25 M sucrose, 1 mM EDTA, 10 mM
glycylglycine and peroxisomes isolated by Nycodenz density gradient
centrifugation of the light mitochondrial fraction [28,29]. DAP-AT
was extracted from these peroxisomes using the CHAPS-based solu-
bilization bu¡er (500 Wl/mg of protein) described by Webber and
Hajra [30]. The samples were sonicated (Branson Soni¢er B-30, Bran-
son, Danbury, CT, USA) at 30% duty and output 3 for 3U20 s on ice
before pelleting the CHAPS-insoluble membrane residue by high
speed centrifugation. Rate sedimentation of CHAPS-extracted DAP-
AT activity was performed by layering the solubilized enzyme on top
of a continuous 15^45% w/w sucrose gradient containing 0.2%
CHAPS and sedimenting DAP-AT activity at 150 000Ug for 15 h
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in a RPV 50 vertical rotor (Hitachi, Tokio, Japan). The DAP-AT
peak fractions were diluted and further puri¢ed by Mono Q anion
exchange chromatography eluting DAP-AT activity by a linear 15^
500 mM NaCl gradient.
The polypeptides of the pooled DAP-AT peak fractions eluted from
the Mono Q column were separated by SDS-PAGE (2.7% C, 7% T).
Three major components exhibiting molecular masses of 76, 72 and
69 kD were visualized. By tryptic digestion [31] the following pep-
tide sequences were obtained: GISDPLSVFEQTEAAAR, EYV-
DPNNIFGNR, WNGWGYNDEK (76 kD); KWDEFEDILEE,
NSVLNSEEIHYVVR, AIQEHPVVLLPSHR, EVFDTYLVPISISY,
KILSENFGSIH (72 kD); ILSENFGSIH (69 kD). The 76 kD peptide
sequences identi¢ed the polypeptide as being ADAP-S and the IL-
SENFGSIH sequence demonstrated that the 72 and 69 kD polypep-
tides are basically identical. According to the peptide sequences ob-
tained from the 72 kD polypeptide the following expressed sequence
tag- (EST-) clones were identi¢ed: AA316351, T77274, AA402300,
AA478758 and AA425273. Except AA316351 and T77274, the clones
contained overlapping sequences and clones AA316351 and
AA425273 contained the 5P- and 3P-end of the cDNA, respectively.
The peptide sequences obtained from the rabbit enzyme matched the
corresponding human sequences of the EST-clones by 100%, suggest-
ing a high homology of the rabbit and human primary structure. The
lacking sequence between AA316351 and T77274 was ampli¢ed by
PCR using a human brain cDNA library (Stratagen, Heidelberg, Ger-
many) as a template. Oligonucleotide probes of the 5P- and 3P-ends of
the identi¢ed cDNA were synthesized in order to screen the human
brain cDNA library. Sequencing (PRISM Ready Reaction Cycle se-
quencing kit with AmpliTaq FS, PE Applied Biosystems and ABI 373
sequencing machine) of the obtained cDNA demonstrated identity to
that assembled from the EST-clones.
Catalase and succinate dehydrogenase activities were assayed as
described [28,32]. DAP-AT activity was determined as in [30] except
total assay volume was reduced to 60 Wl and the radioactive acyl-DAP
collected on Whatman 3 mm ¢lters was washed three times with
decreasing concentrations of trichloroacetic acid (10, 5 and 1%)
each for 5 min at 4‡C.
Monospeci¢c anti-DAP-AT and anti-ADAP-S antisera were raised
in rabbits by injection of their C-terminal peptides, C-EMLGCKK-
PIGKPAT and C-KSVKEYVDPNNIFGNRNLL, respectively, (1
mg/rabbit) coupled to keyhole limpets hemocyanin [33]. Animals
were boostered once or twice at three week intervals with half the
amount of antigen. IgGs of the obtained antisera as well as control
(preimmune) IgGs were coupled to CH-Sepharose 4B (2 mg IgGs/ml
of gel) according to the manufacturer’s recommendations (Pharmacia,
Freiburg, Germany). Immunoprecipitation was carried out by incu-
bating the CHAPS-extracted peroxisomal supernatant (1 Wg of pro-
tein/25 Wl) with 25 Wl packed IgG-Sepharose for 30 min at 37‡C.
Experiments demonstrating the speci¢city of the immunoprecipitation
reaction were performed by preincubating DAP-AT IgG-Sepharose
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Fig. 1. Isolation of puri¢ed peroxisomes of the rabbit Harderian
gland. A: The light mitochondrial fraction of the glandular tissue
was separated by Nycodenz density gradient centrifugation. The
gradient distribution of mitochondria and peroxisomes is demon-
strated by the marker enzymes succinate dehydrogenase (F) and cat-
alase (b), respectively. Distribution of DAP-AT activity is shown by
(R). B: Transmission electron micrograph of isolated Harderian
gland peroxisomes pooled from fractions 4^6 of the Nycodenz gra-
dient demonstrating the high state of puri¢cation. Bar = 0.5 Wm.
Fig. 2. Sedimentation of DAP-AT activity extracted from Harderian
gland peroxisomes following sucrose density gradient centrifugation
in the presence of 0.2% CHAPS in the gradient solution. A: Distri-
bution of DAP-AT activity and protein (F). The polypeptide com-
position of DAP-AT peak fractions 4^9 is visualized by SDS-PAGE
and silver staining (inset). DAP-AT peak fractions from the gradient
(fractions 4^6) were pooled and separated by anion exchange chro-
matography. The elution pro¢le of DAP-AT activity (B) is com-
pared with the polypeptide composition of the eluted fractions after
SDS-PAGE and silver staining (C). Note that DAP-AT activity co-
elutes exactly with the 72 kD polypeptide.
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with 25 Wg of DAP-AT tail peptide for 1 h at 4‡C. DAP-AT activity
bound to IgG-Sepharose was then determined as described above.
Isolated peroxisomes were processed for electron microscopy as
described [28]. For ultrastructural immunolocalization of DAP-AT
rat liver tissue was ¢xed in situ with 0.25% glutaraldehyde in 0.1 M
Pipes-NaOH, pH 7.4, containing 2% sucrose. Tissue slices were
stained with tannic acid (0.25% in Pipes-NaOH, pH 7.4) and uranyl
acetate (1% in 0.05 M sodium maleate, pH 6) prior to embedding in
LR-White.
3. Results
3.1. Isolation of DAP-AT
We used the Harderian gland of the rabbit as a rich source
of DAP-AT activity to isolate a highly puri¢ed peroxisomal
fraction (Fig. 1) which served as starting material for the
isolation of the enzyme. Speci¢c activity of DAP-AT in these
peroxisomes was determined to be 1.8 mU/mg of protein
which is about 500 times that in rat liver peroxisomes. The
subsequent use of di¡erent chromatographic steps [30,34], (i)
gel ¢ltration (Superdex 200), (ii) anion exchange (Mono Q),
(iii) hydroxylapatite, (iv) hydrophobic interaction (Phenylsu-
perose) and (v) chromatofocusing, allowed us to isolate DAP-
AT as a homogeneous 72 kD polypeptide (results not shown).
The amount of protein obtained, however, was to low to
initiate peptide sequencing. Therefore, we decided to enrich
the enzyme prior to chromatography by sucrose density gra-
dient centrifugation. The analysis of this gradient is shown in
Fig. 2A. Surprisingly, DAP-AT activity sedimented as a het-
erooligomeric complex with an apparent mass of about 210
kD that essentially consisted of three polypeptides of 76, 72,
and 69 kD (inset in Fig. 2A). Separation of the DAP-AT peak
fractions from the sucrose gradient by anion exchange chro-
matography revealed that the 72 kD polypeptide exactly co-
eluted with DAP-AT activity (Fig. 2B, C). After tryptic diges-
tion of the three polypeptides we obtained peptide sequences
which revealed that (i) the 76 kD species is identical with
ADAP-S [9] and (ii) the 72 and 69 kD species share peptide
sequences, suggesting that they are basically identical polypep-
tides.
3.2. Molecular characterization of DAP-AT
Based on the peptide sequences we screened cDNA data-
bases and identi¢ed a large number of EST-clones from di¡er-
ent species. Five clones of human species seemed to cover
nearly the entire cDNA sequence. There were overlapping
sequences between clones 2 and 3, 3 and 4, and 4 and 5.
The missing sequence between clones 1 and 2 was ampli¢ed
by PCR. The DAP-AT cDNA sequence put together from the
EST-clones was con¢rmed by sequencing the cDNA obtained
by screening a human brain cDNA library (Scheme 1). The
sequence information is available at the EMBL data library
under the accession number AJ002190 (locus; HSJ002190).
From the nucleotide-derived amino acid sequence we noted
that DAP-AT consists of 680 amino acid residues exhibiting a
molecular mass of 77 187 kD. At the C-terminus DAP-AT
contains a PTS1 represented by the tripeptide AKL which
has also been found in various other peroxisomal matrix pro-
teins [10,35]. Between amino acid residues 165^187, 382^395
and 482^498 there are extended hydrophobic domains which
possibly mediate interaction of DAP-AT with the peroxisomal
membrane.
C-terminal peptides of DAP-AT and ADAP-S were synthe-
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Fig. 3. Immunoprecipitation of DAP-AT activity with anti-DAP-AT
antiserum. A: Monospeci¢city of anti-ADAP-S and anti-DAP-AT
antisera, as demonstrated by SDS-PAGE and immunoblotting of
Harderian gland peroxisomes (6 Wg of protein). B: Immunoprecipi-
tation of DAP-AT activity from Harderian gland peroxisomal
CHAPS-extracts (15 Wg of protein/25 Wl of gel) using anti-DAP-AT
IgGs immobilized to Sepharose 4B (lane C). DAP-AT activity im-
munoprecipitated by the antiserum is represented by black columns,
whereas total DAP-AT activity as well as activity remaining in the
supernate is shown in grey. Preincubation of anti-DAP-AT IgGs
with DAP-AT tail peptide used for immunization strongly inhibited
immunoprecipitation by anti-DAP-AT antiserum (lane D). IgGs of
control serum (lane B) immobilized to Sepharose at the same con-
centration as anti-DAP-AT IgGs were unable to immunoprecipitate
DAP-AT activty.
Fig. 4. Intraperoxisomal localization of DAP-AT by ultrastructural
immunogold labeling. LR-White embedded rat liver sections were
stained with anti-DAP-AT antiserum followed by 14 nm gold-la-
beled protein A. The gold particles are exclusively located to the in-
ner aspect of the peroxisomal membrane. Bar = 0.1 Wm.
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sized to raise antibodies in rabbits. In the C-terminal DAP-
AT peptide used for immunization the last three amino acids
(PTS1) were omitted in order to avoid cross-reactivity with
other PTS1 containing polypeptides. Similar to ADAP-S, pri-
mary structure of DAP-AT seems to be highly conserved
within mammals. Human and mouse cDNAs, for example,
are about 80% homologous to each other. Compared with
the human sequence, the last 14 C-terminal amino acids of
mouse DAP-AT only di¡er at position 670 (K/T). Monospe-
ci¢city of these anti-DAP-AT and anti-ADAP-S antisera for
the Harderian gland peroxisomal antigens is depicted in Fig.
3A. Subsequently, the antibodies were used to immunoprecip-
itate DAP-AT from Harderian gland peroxisomal CHAPS-
extracts. As shown in Fig. 3B, anti-DAP-AT IgGs immobi-
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Scheme 1.
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lized to Sepharose beads are able to speci¢cally precipitate
DAP-AT, whereas immobilized IgGs of control serum failed
to immunoprecipitate the enzyme. Incubation of anti-DAP-
AT IgGs with DAP-AT C-terminal peptide prior to immuno-
precipitation completely abolished binding of DAP-AT to the
Sepharose-bound IgGs, demonstrating the speci¢city of the
immunoprecipitation reaction.
3.3. Intraperoxisomal localization of DAP-AT
Biochemical studies on isolated rat liver peroxisomes indi-
cate DAP-AT and ADAP-S to be localized to the inner aspect
of the peroxisomal membrane [36,37]. Although in intact tis-
sue several matrix enzymes, e.g. acyl CoA oxidase or bifunc-
tional protein are clearly distributed within the matrix, in
isolated peroxisomes they appear to strongly associate with
FEBS 19643 24-12-97
Scheme 1 (continued).
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the membrane. For that reason we analyzed the intraorganel-
lar localization of DAP-AT by ultrastructural immunocyto-
chemistry. Fig. 4 demonstrates that in rat liver the enzyme is
exclusively localized to the lumenal side of the peroxisomal
membrane. This observation is in agreement with biochemical
¢ndings that demonstrate complete extraction of the enzyme
by carbonate (not shown).
4. Discussion
During the initial state of our studies on the isolation of
DAP-AT we followed the procedures of Webber and Hajra
[30] and Ofman and Wanders [34]. These authors provide
valuable data on the isolation and puri¢cation of DAP-AT
from guinea pig liver and human placenta, including choice of
detergent for enzyme extraction and the observation that the
solubilized enzyme has an altered pH-optimum. As starting
material for the isolation of peroxisomes we chose the Har-
derian gland of the rabbit which, like mammalian sebaceous
glands, produces large amounts of EPLs [25,27] serving eye
protection or sebaceous or pheromonal purposes.
Sucrose gradient centrifugation of CHAPS-extracted per-
oxisomes proved to be a favorable step for the enrichment
of DAP-AT, since the enzyme obviously is solubilized as a
trimeric complex which is completely separated by centrifuga-
tion from the vast majority of other peroxisomal proteins
increasing the speci¢c activity of DAP-AT about 5-fold. The
gradient distribution of the 72 kD polypeptide exactly fol-
lowed the distribution of DAP-AT activity. Separation of
DAP-AT peak fractions from the sucrose gradient by anion
exchange chromatography again revealed that this polypep-
tide exactly co-eluted with DAP-AT activity, providing strong
indication for their identity. The 69 kD polypeptide, also
present in the complex, most likely is a modi¢ed form of
DAP-AT, presumably generated by posttranslational modi¢-
cation which still has to be characterized.
The cDNA sequence obtained from the identi¢ed EST-
clones as well as clones of the cDNA library screen coded
for an unknown polypeptide. The C-terminal PTS1 [10,35]
distinguishes the polypeptide as a peroxisomal one and sug-
gests that the C-terminal AKL sequence mediates peroxisomal
targeting of DAP-AT. Screening of protein databases revealed
homologies of human DAP-AT with glycerol-3-phosphate
acyltransferase (GP-AT) of wide species variety, including
rat, mouse, E. coli and Haemophilus in£uenzae. The homolo-
gies are restricted to distinct domains of about 35^80 amino
acid residues in length showing up to 78% similarities and up
to 45% identities. Other homologous proteins include hypo-
thetical 69 and 118 kD polypeptides of Mycobacterium tuber-
culosis and Saccharomyces cerevisiae, respectively.
The striking partial homologies of DAP-AT and GP-AT
strongly underline that the cloned cDNA indeed codes for
DAP-AT. Both enzymes catalyze the transfer of acyl residues
from CoA to a glycerol derivative, thus homologous domains
within these polypeptides were to be expected. Additional evi-
dence that the cloned cDNA codes for DAP-AT is derived
from immunoprecipitation of DAP-AT activity using immo-
bilized IgGs of a monospeci¢c peptide antiserum.
The primary structure of DAP-AT reveals several hydro-
phobic domains which may explain the membrane-bound
character of the enzyme. Membrane association of the enzyme
was already noted previously by the observations that the
enzyme is not solubilized by sonication and only partially
digested by exogenously added protease [36]. The present
studies including ultrastructural immunocytochemistry con-
¢rm this view by demonstrating localization of DAP-AT to
the inner aspect of the rat liver peroxisomal membrane. Since
EL biosynthesis is initiated exclusively within peroxisomes,
and subsequent steps required for its completion are localized
to the ER, EL intermediates have to be transported from
peroxisomes to the ER. Thus, it is tempting to speculate
that the EL biosynthetic apparatus, including DAP-AT and
ADAP-S, as well as an ADAP/alkyl-GP transporter build up
a functional unit for the export of EL precursors. This trans-
porter still needs to be identi¢ed.
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